NCT01571518

Prevention of Neutropenia After Using G-CSF With TAC Chemotherapy

Optimal Timing and Duration of Daily G-CSF With Adjuvant TAC Chemotherapy in Node-positive Breast Cancer;Multicenter, Randomized, Open Label, Clinically IV Phase

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Hyuk moon Kim · Academic / Other
• Sex: Female
• Age: 20 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

After resection of lymph node positive breast cancer, the injection duration and timing of Granulocyte-colony stimulating factor (G-CSF) could affect the neutropenia with TAC (Taxotere, Adriamycin, cyclophosphamide) chemotherapy.

Detailed description

The duration and the injection timing of G-CSF are effective in the prevention of neutropenia, incidence of infection and non hematologic toxicity. With the TAC chemotherapy after resection of breast cancer, the G-CSF early injection versus late injection could change the frequency of neutropenia.

Conditions

• Neutropenia

Interventions

Type	Name	Description
DRUG	late leukostim	injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy
DRUG	early leukostim	injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy

Timeline

• Start date: 2012-04-01
• Primary completion: 2013-10-01
• Completion: 2013-10-01
• First posted: 2012-04-05
• Last updated: 2012-04-05

Locations

1 site across 1 country: South Korea